Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Subject-reported compliance in a chemoprevention trial for familial adenomatous polyposis


A high level of compliance with an assigned treatment regimen is fundamental to accurate assessment of treatment effectiveness in any clinical trial. If compliance is poor, an effective treatment may be confounded by inadequate delivery of the regimen. Although much research has focused on broad aspects of compliance dealing with clinical therapeutic situations, there was a need for further research dealing specifically with adherence issues in a long-term chemoprevention trial since subject motivation in the latter is likely to differ from that of the former. Examining subject-reported compliance over the first 2-year treatment periods of a long-term chemoprevention trial for familial adenomatous polyposis, it was found that (1) compliance decreased over time, (2) fiber compliance was lower than vitamin compliance, and (3) four explanatory variables which may be amenable to individualized study-team interventions emerged as useful prognosticators of fiber compliance.

This is a preview of subscription content, log in to check access.


  1. Andrews, F. M., and Withey, S. B. (1976).Social Indicators of Well-Being: Americans' Perceptions of Life Quality, Plenum, New York.

  2. Baron, J. A. (1984). Compliance issues/biological markers. In Sestili, M. A. (ed.),Chemoprevention Clinical Trials: Problems and Solutions, NIH Publication No. 85-2715, U.S. Dept. Health Hum. Serv., pp. 44–48.

  3. Becker, M. H. (1976). Sociobehavioral determinants of compliance. In Sackett, D. L., and Haynes, R. B., (eds.),Compliance with Therapeutic Regimens, Johns Hopkins University Press, Baltimore.

  4. Bradburn, N. M. (1969).The Structure of Psychological Well-Being, Aldine, Chicago.

  5. Bussey, H. J. R., DeCosse, J. J., Deschner, E. E., Eyers, A. A., Lesser, M. L., Morson, B. C., Ritchie, S. M., Thomson, J. P. S., and Wadsworth, J. (1982). A randomized trial of ascorbic acid in polyposis coli.Cancer 50: 1434–1439.

  6. Byar, D. P. (1984). Sample size considerations for prevention studies. In Sestili, M. A. (ed.),Chemoprevention Clinical Trials: Problems and Solutions, NIH Publication No. 85-2715, U.S. Dept. Health Hum. Serv. pp. 14–20.

  7. Cohen, J. (1977).Statistical Power Analysis for the Behavioral Sciences, Academic Press, New York.

  8. Daly, J. M., Miller, H. H., Besser, P., Groshen, S., and DeCosse, J. J. (1985). Effect of dietary fiber on intestinal transit times in operated patients with familial polyposis.J. Surg. Oncol. 30: 174–176.

  9. Eraker, S. A., Kirscht, J. P., and Becker, M. H. (1984). Understanding and improving patient compliance.Ann. Intern. Med. 100: 258–268.

  10. Evans, A. M., Love, R. R., Meyerowitz, B. E., Leventhal, H., and Nerenz, D. R. (1985). Factors associated with active participation in a cancer prevention clinic.Prev. Med. 14: 358–371.

  11. Haynes, R. B. (1976). A critical review of the determinants of patient compliance with therapeutic regimens. In Sackett, D. L., and Haynes, R. B. (eds.),Compliance with Therapeutic Regimens, Johns Hopkins University Press, Baltimore.

  12. Haynes, R. B., Taylor, D. W., and Sackett, D. L. (eds.) (1979).Compliance in Health Care, Johns Hopkins University Press, Baltimore.

  13. Ho, E. E., Loescher, L., Hurd, P., Abrams, C., Atwood, J., Sheehan, E., Moon, T., and Meyskens, F. (1987). Compliance issues in cancer prevention and control trials (submitted for publication).

  14. Maiman, L. A., and Becker, M. H. (1974). The Health Belief Model: origins and correlates in psychological theory.Health Educ. Monogr. 2: 336–355.

  15. Marston, M. (1970). Compliance with medical regimens: A review of the literature.Nurs. Res. 19: 312–323.

  16. Matthews, D., and Hingson, R. (1977). Improving patient compliance: A guide for physicians.Med. Clin. No. Am. 61: 879–889.

  17. Miller, H. H., Bauman, L. J., Friedman, D. R., and DeCosse, J. J. (1986–1987). Psychosocial adjustment of familial polyposis patients and participation in a chemoprevention trial.Int. J. Psychiat. Med. 16: 211–230.

  18. Mitchell, J. (1974). Compliance with medical regimens: An annotated bibliography.Health Educ. Monogr. 2: 75–87.

  19. Sener, S. F., Miller, H. H., and DeCosse, J. J. (1984). The spectrum of polyposis.Surg. Gynecol. Obstet. 159: 525–532.

  20. Wallston, B. S., Wallston, K. A., Kaplan, G. D., and Maides, S. A. (1976). Development and validation of the health locus of control scale.J. Consult. Clin. Psychol. 44: 580–585.

Download references

Author information

Correspondence to Mark Berenson.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Berenson, M., Groshen, S., Miller, H. et al. Subject-reported compliance in a chemoprevention trial for familial adenomatous polyposis. J Behav Med 12, 233–247 (1989).

Download citation

Key words

  • chemoprevention trial
  • familial adenomatous polyposis
  • compliance